SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
SeaStar Medical (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. ET / 2:30 p.m. MT to discuss its financial performance and business updates. Investors can access the call using Conference ID 2078693, with dial-in numbers 1 (800) 715-9871 (U.S.) and 1 (646) 307-1963 (international). A replay will be available until August 20, 2025.
SeaStar Medical (Nasdaq: ICU), un'azienda sanitaria in fase commerciale specializzata in trattamenti per pazienti critici con insufficienza d'organo, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 13 agosto 2025, al termine delle contrattazioni.
L'azienda terrà una conference call e una webcast alle 16:30 ET / 14:30 MT per discutere le performance finanziarie e gli aggiornamenti aziendali. Gli investitori potranno accedere alla chiamata utilizzando l'ID conferenza 2078693, con i numeri di telefono 1 (800) 715-9871 (USA) e 1 (646) 307-1963 (internazionale). Una registrazione sarà disponibile fino al 20 agosto 2025.
SeaStar Medical (Nasdaq: ICU), una empresa sanitaria en etapa comercial especializada en tratamientos para pacientes críticamente enfermos con insuficiencia orgánica, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 13 de agosto de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia y una transmisión web a las 4:30 p.m. ET / 2:30 p.m. MT para discutir su desempeño financiero y actualizaciones comerciales. Los inversionistas pueden acceder a la llamada usando el ID de conferencia 2078693, con los números telefónicos 1 (800) 715-9871 (EE.UU.) y 1 (646) 307-1963 (internacional). Una repetición estará disponible hasta el 20 de agosto de 2025.
SeaStar Medical (Nasdaq: ICU)는 장기 부전으로 위중한 환자를 위한 치료에 특화된 상업 단계 의료 회사로, 2025년 8월 13일 장 마감 후 2025년 2분기 재무 결과 발표를 예정하고 있습니다.
회사는 재무 실적 및 사업 업데이트를 논의하기 위해 오후 4:30 ET / 오후 2:30 MT에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 컨퍼런스 ID 2078693를 사용하여 전화 접속할 수 있으며, 미국 내 전화번호는 1 (800) 715-9871, 국제 전화번호는 1 (646) 307-1963입니다. 녹음된 방송은 2025년 8월 20일까지 제공됩니다.
SeaStar Medical (Nasdaq : ICU), une entreprise de santé en phase commerciale spécialisée dans les traitements pour les patients gravement malades souffrant d'insuffisance organique, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 13 août 2025, après la clôture du marché.
L'entreprise animera une conférence téléphonique et une webdiffusion à 16h30 ET / 14h30 MT pour discuter de ses performances financières et des mises à jour commerciales. Les investisseurs peuvent accéder à l'appel en utilisant l'ID de conférence 2078693, avec les numéros d'appel 1 (800) 715-9871 (États-Unis) et 1 (646) 307-1963 (international). Une rediffusion sera disponible jusqu'au 20 août 2025.
SeaStar Medical (Nasdaq: ICU), ein Unternehmen im kommerziellen Stadium, das sich auf Behandlungen für kritisch kranke Patienten mit Organversagen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 13. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird eine Telefonkonferenz und einen Webcast um 16:30 Uhr ET / 14:30 Uhr MT abhalten, um die finanzielle Leistung und Geschäftsentwicklungen zu besprechen. Investoren können die Konferenz mit der ID 2078693 über die Telefonnummern 1 (800) 715-9871 (USA) und 1 (646) 307-1963 (international) erreichen. Eine Aufzeichnung ist bis zum 20. August 2025 verfügbar.
- None.
- None.
DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Wednesday, August 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here. |
| Conference ID: | 2078693 |
| Dial-in numbers: | 1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S. |
A replay of the call will be available after 7:30 pm ET and can be accessed as follows:
- The webcast replay is available here.
- The call replay number is 1 (609) 800-9909 and will be available through August 20, 2025.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
When will SeaStar Medical (ICU) report Q2 2025 earnings?
How can investors join SeaStar Medical's Q2 2025 earnings call?
Until when will SeaStar Medical's Q2 2025 earnings call replay be available?
What time is SeaStar Medical's Q2 2025 earnings call?
